No Data
Intellia Therapeutics Is Maintained at Neutral by Goldman Sachs
Intellia Therapeutics Price Target Lowered to $19 From $25 at Citi
Intellia Therapeutics' NTLA-2002: Hold Rating Amid Competitive Challenges and Safety Concerns
Intellia Therapeutics: Promising Phase 2 Results and Growth Potential Justify Buy Rating
7 Analysts Have This To Say About Intellia Therapeutics
BofA Securities Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $65
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday